Last reviewed · How we verify

NCT03502226: iRAP

Evaluation of an Inpatient Sexual Risk Behavior Assessment Program

Completed NA Last updated 18 April 2018
What this trial tests

NA trial testing Tailored feedback in Adolescent Behavior in 66 participants. Completed in 29 October 2017.

Timeline
4 January 2017
Primary endpoint
29 October 2017
29 October 2017

Quick facts

Lead sponsorRhode Island Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment66
Start date4 January 2017
Primary completion29 October 2017
Estimated completion29 October 2017

Drugs / interventions tested

Conditions studied

Sponsor

Rhode Island Hospital

Who can join

Adults 14 to 18, female only, with Adolescent Behavior or Sexual Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory pilot study to evaluate the feasibility and potential effects of an innovative, individualized electronic inpatient sexual health intervention (iRAP) for adolescent females. The central hypothesis is that the electronic intervention, a sexual health questionnaire with tailored feedback based on the Trans Theoretical Model (TTM) of behavior change, will significantly increase adolescent females' requests for sexually transmitted infection (STI) screening and sexual health management during their hospital admission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Adolescent Behavior

Currently open trials in the same condition.

Other Rhode Island Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03502226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing